Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Stopped Due to former trials, drug has not demonstrated a clinical profile sufficient to move forward in mCRPC

Conditions

• Prostate Cancer

Interventions

• DRUG: Orteronel
• DRUG: Placebo

Sponsor

Swiss Cancer Institute